Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01827319 · ClinicalTrials.gov registry record

Cardiogenesis Transmyocardial Revascularization Registry

A clinical trial of Class IV Angina, sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife.

Completed
Registry status
203
Enrollment target
20
Study locations

NCT01827319: Completed study of Class IV Angina, sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife.

NCT01827319 is a study of Class IV Angina that has completed, run by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife. The registered enrollment target is 203 participants. The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01827319, a study of Class IV Angina, has completed, sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife.

COMPLETED
Registry status
203 participants
Enrollment target
20
Study locations

Study Summary

The objectives of the registry are as follows: * Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System; * Further define the disease characteristics of the population being treated; * Examine transmyocardial revascularization (TMR) usage characteristics and 30-day outcomes; * Further assess the 30-day postoperative risk factors for adverse events. To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria are to be offered the opportunity to enroll in the study at participating centers.

Primary Outcome

Number of Participant Deaths

Conditions Studied

Study Locations (20)

California

  • California Cardiac Surgeons - Bakersfield
  • The Vo Group - Fountain Valley
  • Hurwitz & Roberts Med Corp - Glendale
  • Advanced Cardiothoracic Surgery Medical Group - Los Angeles
  • Soltero & Yasuda Associates Cardiothoracic & Vascular Medical Group - Northridge
  • Cardiovascular & Thoracic Surgeons of Ventura County, APC - Oxnard
  • Joseph W. Wilson, MD, Inc. - Rancho Mirage
  • Sutter Institute for Medical Research - Sacramento

Florida

  • Bethesda Memorial Hospital - Boynton Beach
  • Broward Health Medical Center - Fort Lauderdale
  • Cardiothoracic and Vascular Surgical Associates - Jacksonville
  • Coastal Cardiovascular and Thoracic Associates, PA - Ormond Beach

Kentucky

  • Lexington Cardiac Research Foundation, Inc. - Lexington
  • Owensboro Health, Inc. - Owensboro
  • Regional Heart & Lung Surgery - Paducah

Arizona

  • University of Arizona - Tuscon

Georgia

  • Georgia Health Sciences University Research Institute, Inc. - Augusta

Missouri

  • Saint Luke's Hospital - Kansas City

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • The Feinstein Institute for Medical Research - New York

Trial Details

FieldValue
Enrollment Target 203 participants
Start Date 2013-05
Est. Completion 2015-06

What the finished NCT01827319 record still lists

NCT01827319 is an observational study that tracks outcomes without assigning an intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap.

The record links to 1 condition, with Class IV Angina appearing as the primary indexed condition, and to 0 interventions.

NCT01827319 names 20 study sites across 8 states, led by California, Florida, Kentucky.

Frequently Asked Questions

What is clinical trial NCT01827319 about?

NCT01827319 is a clinical study titled "Cardiogenesis Transmyocardial Revascularization Registry". The objectives of the registry are as follows: * Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System; * Further define the disease characteristics of the population being treated; * Examine transmyocardial revascularization (TMR) usage characteristi...

What is the current status of trial NCT01827319?

This trial is currently completed. The enrollment target is 203 participants. The study started on 2013-05. Estimated completion is 2015-06.

What conditions does trial NCT01827319 study?

This clinical trial studies the following conditions: Class IV Angina.

Who is sponsoring clinical trial NCT01827319?

This trial is sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01827319 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05652686 · 203 participants · Phase 1

    A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • NCT06063122 · 203 participants · NA

    Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

  • NCT07031245 · 203 participants · NA

    Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01827319, the US trial registry maintained by the National Library of Medicine. NCT01827319 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.